Compound research
Tesamorelin: Research Overview & Current Status
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH/GRF) analog. Current research status: fda-approved. Tesamorelin is FDA-approved (Egrifta, later Egrifta SV and Egrifta WR) for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It has no FDA-approved indication for general weight loss, bodybuilding, or anti-aging use.
Overview
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) developed by Theratechnologies. It is administered by daily subcutaneous injection and stimulates endogenous growth hormone production; it was the first FDA-approved treatment specifically for HIV-associated lipodystrophy.
synthetic growth hormone-releasing hormone (GHRH/GRF) analog
Research timeline
2010
FDA approved Egrifta (tesamorelin) for HIV-associated lipodystrophy based on two Phase 3 trials pooling 816 HIV-infected adults.
Source →2019
Reformulated Egrifta SV approved, replacing the original Egrifta formulation.
Source →2025
FDA approved a supplemental Biologics License Application for Egrifta WR (Tesamorelin F8), a longer-acting formulation requiring weekly rather than daily reconstitution.
Source →2025
FDA approved a Prior Approval Supplement for Egrifta SV, removing a discretionary product-release requirement and allowing resumed regular distribution.
Source →
Active & recent research
Post-marketing long-term observational study (FDA-required)
long-term risks including major adverse cardiac events (MACE), cancer risk, and hypersensitivity reactions
Retinopathy risk study in patients with type 2 diabetes
assessing retinopathy risk associated with GH-axis stimulation in a diabetic population
Key findings
- Pooled Phase 3 data across 806 participants in two trials reported approximately 15.4% reduction in visceral adipose tissue versus placebo at 26 weeks (p<0.001), with concurrent reductions in fasting triglycerides.
- FDA's approval basis specifically applied to HIV-associated lipodystrophy; the agency has noted that improvement in net health outcome (beyond visceral fat reduction) has not been established, and long-term cardiovascular benefit has not been directly studied in a randomized trial, which FDA considers infeasible given event rates.
- Reformulation research (Egrifta WR / F8) reported bioequivalence to the original formulation while enabling weekly reconstitution and less than half the injection volume of its predecessor.
Safety & regulatory notes
Tesamorelin (Egrifta/Egrifta SV/Egrifta WR) is FDA-approved specifically for HIV-associated lipodystrophy; it carries no approved indication for general obesity, bodybuilding, or anti-aging use, and the FDA has required post-marketing studies on cardiovascular, cancer, hypersensitivity, and retinopathy risks. Non-brand or 'research chemical' tesamorelin sold outside the approved pharmaceutical supply chain is not FDA-reviewed for identity, purity, or safety.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
Where it's sold for research
We haven't built a dedicated vendor-availability page for Tesamorelin yet. See our full research-peptide vendor rankings →
Tesamorelin FAQ
Is tesamorelin FDA-approved?+
Yes, under the brand names Egrifta, Egrifta SV, and Egrifta WR, specifically for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
What is tesamorelin studied for?+
Its approved use is visceral fat reduction in HIV-associated lipodystrophy; FDA-required post-marketing studies are examining long-term cardiovascular, cancer, hypersensitivity, and retinopathy risk.
Is tesamorelin approved for weight loss or anti-aging in the general population?+
No. The FDA has stated there is no approved indication for obesity, general belly fat, bodybuilding, or anti-aging use.
Is compounded or research-grade tesamorelin the same as Egrifta?+
No. Egrifta and its reformulations are FDA-approved, manufactured, and tested pharmaceutical products; tesamorelin sold as a research chemical outside that supply chain has not undergone the same regulatory review.
Sources for this page (4)
- 1 https://www.managedhealthcareexecutive.com/view/fda-approves-tesamorelin-hiv-patients-lipodystrophy
- 2 https://www.contagionlive.com/view/fda-approves-f8-formulation-of-theratechnologies-tesamorelin-for-hiv-associated-lipodystrophy
- 3 https://www.premera.com/medicalpolicies/5.01.530.pdf
- 4 https://www.mass.gov/doc/issue-1-february-2017-1/download
Related: all compound research overviews · research radar · full vendor rankings · methodology